Global Radionuclide Drug Conjugates (RDC) Market Growth (Status and Outlook) 2026-2032
The global Radionuclide Drug Conjugates (RDC) market size is predicted to grow from US$ 9295 million in 2025 to US$ 14850 million in 2032; it is expected to grow at a CAGR of 7.1% from 2026 to 2032.
Radionuclide-conjugated drugs (RCDs) are complex molecules for precise targeted therapy and diagnosis, composed of three core elements: a targeting ligand, a linker, and a radionuclide. Their mechanism of action is similar to a 'biologically guided miniature nuclear bomb': the targeting ligand specifically recognizes and binds to biomarkers highly expressed on the surface of diseased cells such as tumors; the linker ensures the stability of the entire molecule; and the radionuclide acts as the 'warhead,' accumulating at the target site and releasing ionizing radiation energy such as alpha and beta particles to destroy tumor cells from within, or releasing gamma/positron rays for highly sensitive molecular imaging diagnosis. This design achieves precise, 'visualized' targeting of diseases and is a prime example of the deep integration of nuclear medicine and targeted drug technology.
The field of RCDs is experiencing explosive growth, with a broad and clear development prospect. Future trends will focus on: first, target diversification and drug iteration, with RDCs targeting new targets such as CLDN18.2 and FAP rapidly entering clinical trials, and the development of better ligands. Second, the advancement of treatment paradigms: the highly promising alpha radionuclide therapy holds the potential to conquer more complex and drug-resistant solid tumors, becoming a core next-generation treatment method. Third, the deep integration of diagnosis and treatment: patient stratification and personalized dosage regimens based on precise imaging will become standard procedures, greatly improving treatment efficiency and safety. Fourth, technological platform innovation: more stable connectivity technologies, prodrug strategies, and combination therapies will continuously expand its application boundaries. Overall, RDC is evolving from a 'powerful tool' for a few specific cancer types into an indispensable precision diagnosis and treatment platform in oncology and even some non-oncology diseases.
LPI (LP Information)' newest research report, the “Radionuclide Drug Conjugates (RDC) Industry Forecast” looks at past sales and reviews total world Radionuclide Drug Conjugates (RDC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugates (RDC) sales for 2026 through 2032. With Radionuclide Drug Conjugates (RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radionuclide Drug Conjugates (RDC) industry.
This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugates (RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugates (RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radionuclide Drug Conjugates (RDC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugates (RDC) and breaks down the forecast by Targeted Ligands, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugates (RDC).
This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugates (RDC) market by product type, application, key players and key regions and countries.
Segmentation by Targeted Ligands:
Radionuclide-conjugated drugs (RCDs) are complex molecules for precise targeted therapy and diagnosis, composed of three core elements: a targeting ligand, a linker, and a radionuclide. Their mechanism of action is similar to a 'biologically guided miniature nuclear bomb': the targeting ligand specifically recognizes and binds to biomarkers highly expressed on the surface of diseased cells such as tumors; the linker ensures the stability of the entire molecule; and the radionuclide acts as the 'warhead,' accumulating at the target site and releasing ionizing radiation energy such as alpha and beta particles to destroy tumor cells from within, or releasing gamma/positron rays for highly sensitive molecular imaging diagnosis. This design achieves precise, 'visualized' targeting of diseases and is a prime example of the deep integration of nuclear medicine and targeted drug technology.
The field of RCDs is experiencing explosive growth, with a broad and clear development prospect. Future trends will focus on: first, target diversification and drug iteration, with RDCs targeting new targets such as CLDN18.2 and FAP rapidly entering clinical trials, and the development of better ligands. Second, the advancement of treatment paradigms: the highly promising alpha radionuclide therapy holds the potential to conquer more complex and drug-resistant solid tumors, becoming a core next-generation treatment method. Third, the deep integration of diagnosis and treatment: patient stratification and personalized dosage regimens based on precise imaging will become standard procedures, greatly improving treatment efficiency and safety. Fourth, technological platform innovation: more stable connectivity technologies, prodrug strategies, and combination therapies will continuously expand its application boundaries. Overall, RDC is evolving from a 'powerful tool' for a few specific cancer types into an indispensable precision diagnosis and treatment platform in oncology and even some non-oncology diseases.
LPI (LP Information)' newest research report, the “Radionuclide Drug Conjugates (RDC) Industry Forecast” looks at past sales and reviews total world Radionuclide Drug Conjugates (RDC) sales in 2025, providing a comprehensive analysis by region and market sector of projected Radionuclide Drug Conjugates (RDC) sales for 2026 through 2032. With Radionuclide Drug Conjugates (RDC) sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radionuclide Drug Conjugates (RDC) industry.
This Insight Report provides a comprehensive analysis of the global Radionuclide Drug Conjugates (RDC) landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Radionuclide Drug Conjugates (RDC) portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Radionuclide Drug Conjugates (RDC) market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radionuclide Drug Conjugates (RDC) and breaks down the forecast by Targeted Ligands, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radionuclide Drug Conjugates (RDC).
This report presents a comprehensive overview, market shares, and growth opportunities of Radionuclide Drug Conjugates (RDC) market by product type, application, key players and key regions and countries.
Segmentation by Targeted Ligands:
- Small molecules
- Peptides
- Antibodies
- Therapeutic RDCs
- Diagnostic RDCs
- Alpha Nuclide RDCs
- Beta Nuclide RDCs
- Prostate Cancer
- Neuroendocrine Tumors
- Liver Cancer
- Kidney Cancer
- Bone Metastases
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Novartis
- Eli Lilly
- Bayer
- Johnson & Johnson
- Bristol-Myers Squibb
- AstraZeneca
- China Isotope & Radiation Corporation
- Dongcheng Pharmaceutical
- Grand Pharmaceutical Group
- Hengrui Medicine
- Bivision
- SmartNuclide
- Hexin (Suzhou) Pharmaceutical Technology Co., Ltd.
- Xiantong Pharmaceutical
- Full-Life Technologies
- Nuoyu Pharmaceutical
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radionuclide Drug Conjugates (RDC) Market Size (2021-2032)
2.1.2 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Radionuclide Drug Conjugates (RDC) by Country/Region (2021, 2025 & 2032)
2.2 Radionuclide Drug Conjugates (RDC) Segment by Type
2.2.1 Antibody Radionuclide Conjugates (ARC)
2.2.2 Peptide Radionuclide Conjugates (PRC)
2.2.3 Small Molecular Radionuclide Conjugates (SMRC)
2.2.4 Radionuclide Drug Conjugates (RDC) Market Size by Type
2.2.4.1 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
2.3 Radionuclide Drug Conjugates (RDC) Segment by Application
2.3.1 Neuroendocrine Tumors
2.3.2 Prostate Cancer
2.3.3 Renal Cell Carcinoma
2.3.4 Radionuclide Drug Conjugates (RDC) Market Size by Application
2.3.4.1 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
3 RADIONUCLIDE DRUG CONJUGATES (RDC) MARKET SIZE BY PLAYER
3.1 Radionuclide Drug Conjugates (RDC) Market Size Market Share by Player
3.1.1 Global Radionuclide Drug Conjugates (RDC) Revenue by Player (2021-2026)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player (2021-2026)
3.2 Global Radionuclide Drug Conjugates (RDC) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RADIONUCLIDE DRUG CONJUGATES (RDC) BY REGION
4.1 Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026)
4.2 Global Radionuclide Drug Conjugates (RDC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.4 APAC Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.5 Europe Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.6 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026)
5.2 Americas Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
5.3 Americas Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026)
6.2 APAC Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
6.3 APAC Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) by Region (2021-2026)
8.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
8.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RADIONUCLIDE DRUG CONJUGATES (RDC) MARKET FORECAST
10.1 Global Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.1.1 Global Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.1.2 Americas Radionuclide Drug Conjugates (RDC) Forecast
10.1.3 APAC Radionuclide Drug Conjugates (RDC) Forecast
10.1.4 Europe Radionuclide Drug Conjugates (RDC) Forecast
10.1.5 Middle East & Africa Radionuclide Drug Conjugates (RDC) Forecast
10.2 Americas Radionuclide Drug Conjugates (RDC) Forecast by Country (2027-2032)
10.2.1 United States Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.2 Canada Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.3 Mexico Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.4 Brazil Market Radionuclide Drug Conjugates (RDC) Forecast
10.3 APAC Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.3.1 China Radionuclide Drug Conjugates (RDC) Market Forecast
10.3.2 Japan Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.3 Korea Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.4 Southeast Asia Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.5 India Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.6 Australia Market Radionuclide Drug Conjugates (RDC) Forecast
10.4 Europe Radionuclide Drug Conjugates (RDC) Forecast by Country (2027-2032)
10.4.1 Germany Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.2 France Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.3 UK Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.4 Italy Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.5 Russia Market Radionuclide Drug Conjugates (RDC) Forecast
10.5 Middle East & Africa Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.5.1 Egypt Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.2 South Africa Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.3 Israel Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.4 Turkey Market Radionuclide Drug Conjugates (RDC) Forecast
10.6 Global Radionuclide Drug Conjugates (RDC) Forecast by Type (2027-2032)
10.7 Global Radionuclide Drug Conjugates (RDC) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Radionuclide Drug Conjugates (RDC) Forecast
11 KEY PLAYERS ANALYSIS
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Information
11.1.2 POINT Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 POINT Biopharma Main Business Overview
11.1.5 POINT Biopharma Latest Developments
11.2 Telix
11.2.1 Telix Company Information
11.2.2 Telix Radionuclide Drug Conjugates (RDC) Product Offered
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Telix Main Business Overview
11.2.5 Telix Latest Developments
11.3 ITM AG
11.3.1 ITM AG Company Information
11.3.2 ITM AG Radionuclide Drug Conjugates (RDC) Product Offered
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ITM AG Main Business Overview
11.3.5 ITM AG Latest Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Information
11.4.2 Bayer AG Radionuclide Drug Conjugates (RDC) Product Offered
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer AG Main Business Overview
11.4.5 Bayer AG Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Radionuclide Drug Conjugates (RDC) Product Offered
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Lantheus
11.6.1 Lantheus Company Information
11.6.2 Lantheus Radionuclide Drug Conjugates (RDC) Product Offered
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Lantheus Main Business Overview
11.6.5 Lantheus Latest Developments
11.7 Curium Pharma
11.7.1 Curium Pharma Company Information
11.7.2 Curium Pharma Radionuclide Drug Conjugates (RDC) Product Offered
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharma Main Business Overview
11.7.5 Curium Pharma Latest Developments
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Information
11.8.2 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product Offered
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Uihc Pet Imaging Main Business Overview
11.8.5 Uihc Pet Imaging Latest Developments
11.9 Grand Pharma
11.9.1 Grand Pharma Company Information
11.9.2 Grand Pharma Radionuclide Drug Conjugates (RDC) Product Offered
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Grand Pharma Main Business Overview
11.9.5 Grand Pharma Latest Developments
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Information
11.10.2 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product Offered
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BoomRay Pharmaceuticals Main Business Overview
11.10.5 BoomRay Pharmaceuticals Latest Developments
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Information
11.11.2 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SmartNuclide Biopharma Main Business Overview
11.11.5 SmartNuclide Biopharma Latest Developments
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Information
11.12.2 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product Offered
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Hengrui Medicine Main Business Overview
11.12.5 Hengrui Medicine Latest Developments
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Information
11.13.2 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product Offered
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Yunnan Baiyao Group Main Business Overview
11.13.5 Yunnan Baiyao Group Latest Developments
11.14 Sinotau
11.14.1 Sinotau Company Information
11.14.2 Sinotau Radionuclide Drug Conjugates (RDC) Product Offered
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sinotau Main Business Overview
11.14.5 Sinotau Latest Developments
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Information
11.15.2 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product Offered
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Hexin Pharmaceutical Main Business Overview
11.15.5 Hexin Pharmaceutical Latest Developments
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Information
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product Offered
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Main Business Overview
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Radionuclide Drug Conjugates (RDC) Market Size (2021-2032)
2.1.2 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Radionuclide Drug Conjugates (RDC) by Country/Region (2021, 2025 & 2032)
2.2 Radionuclide Drug Conjugates (RDC) Segment by Type
2.2.1 Antibody Radionuclide Conjugates (ARC)
2.2.2 Peptide Radionuclide Conjugates (PRC)
2.2.3 Small Molecular Radionuclide Conjugates (SMRC)
2.2.4 Radionuclide Drug Conjugates (RDC) Market Size by Type
2.2.4.1 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
2.3 Radionuclide Drug Conjugates (RDC) Segment by Application
2.3.1 Neuroendocrine Tumors
2.3.2 Prostate Cancer
2.3.3 Renal Cell Carcinoma
2.3.4 Radionuclide Drug Conjugates (RDC) Market Size by Application
2.3.4.1 Radionuclide Drug Conjugates (RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.3.4.2 Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
3 RADIONUCLIDE DRUG CONJUGATES (RDC) MARKET SIZE BY PLAYER
3.1 Radionuclide Drug Conjugates (RDC) Market Size Market Share by Player
3.1.1 Global Radionuclide Drug Conjugates (RDC) Revenue by Player (2021-2026)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player (2021-2026)
3.2 Global Radionuclide Drug Conjugates (RDC) Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 RADIONUCLIDE DRUG CONJUGATES (RDC) BY REGION
4.1 Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026)
4.2 Global Radionuclide Drug Conjugates (RDC) Annual Revenue by Country/Region (2021-2026)
4.3 Americas Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.4 APAC Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.5 Europe Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
4.6 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026)
5.2 Americas Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
5.3 Americas Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026)
6.2 APAC Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
6.3 APAC Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) by Region (2021-2026)
8.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026)
8.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL RADIONUCLIDE DRUG CONJUGATES (RDC) MARKET FORECAST
10.1 Global Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.1.1 Global Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.1.2 Americas Radionuclide Drug Conjugates (RDC) Forecast
10.1.3 APAC Radionuclide Drug Conjugates (RDC) Forecast
10.1.4 Europe Radionuclide Drug Conjugates (RDC) Forecast
10.1.5 Middle East & Africa Radionuclide Drug Conjugates (RDC) Forecast
10.2 Americas Radionuclide Drug Conjugates (RDC) Forecast by Country (2027-2032)
10.2.1 United States Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.2 Canada Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.3 Mexico Market Radionuclide Drug Conjugates (RDC) Forecast
10.2.4 Brazil Market Radionuclide Drug Conjugates (RDC) Forecast
10.3 APAC Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.3.1 China Radionuclide Drug Conjugates (RDC) Market Forecast
10.3.2 Japan Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.3 Korea Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.4 Southeast Asia Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.5 India Market Radionuclide Drug Conjugates (RDC) Forecast
10.3.6 Australia Market Radionuclide Drug Conjugates (RDC) Forecast
10.4 Europe Radionuclide Drug Conjugates (RDC) Forecast by Country (2027-2032)
10.4.1 Germany Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.2 France Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.3 UK Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.4 Italy Market Radionuclide Drug Conjugates (RDC) Forecast
10.4.5 Russia Market Radionuclide Drug Conjugates (RDC) Forecast
10.5 Middle East & Africa Radionuclide Drug Conjugates (RDC) Forecast by Region (2027-2032)
10.5.1 Egypt Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.2 South Africa Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.3 Israel Market Radionuclide Drug Conjugates (RDC) Forecast
10.5.4 Turkey Market Radionuclide Drug Conjugates (RDC) Forecast
10.6 Global Radionuclide Drug Conjugates (RDC) Forecast by Type (2027-2032)
10.7 Global Radionuclide Drug Conjugates (RDC) Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Radionuclide Drug Conjugates (RDC) Forecast
11 KEY PLAYERS ANALYSIS
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Information
11.1.2 POINT Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 POINT Biopharma Main Business Overview
11.1.5 POINT Biopharma Latest Developments
11.2 Telix
11.2.1 Telix Company Information
11.2.2 Telix Radionuclide Drug Conjugates (RDC) Product Offered
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Telix Main Business Overview
11.2.5 Telix Latest Developments
11.3 ITM AG
11.3.1 ITM AG Company Information
11.3.2 ITM AG Radionuclide Drug Conjugates (RDC) Product Offered
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 ITM AG Main Business Overview
11.3.5 ITM AG Latest Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Information
11.4.2 Bayer AG Radionuclide Drug Conjugates (RDC) Product Offered
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer AG Main Business Overview
11.4.5 Bayer AG Latest Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Radionuclide Drug Conjugates (RDC) Product Offered
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Novartis Main Business Overview
11.5.5 Novartis Latest Developments
11.6 Lantheus
11.6.1 Lantheus Company Information
11.6.2 Lantheus Radionuclide Drug Conjugates (RDC) Product Offered
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Lantheus Main Business Overview
11.6.5 Lantheus Latest Developments
11.7 Curium Pharma
11.7.1 Curium Pharma Company Information
11.7.2 Curium Pharma Radionuclide Drug Conjugates (RDC) Product Offered
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Curium Pharma Main Business Overview
11.7.5 Curium Pharma Latest Developments
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Information
11.8.2 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product Offered
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Uihc Pet Imaging Main Business Overview
11.8.5 Uihc Pet Imaging Latest Developments
11.9 Grand Pharma
11.9.1 Grand Pharma Company Information
11.9.2 Grand Pharma Radionuclide Drug Conjugates (RDC) Product Offered
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Grand Pharma Main Business Overview
11.9.5 Grand Pharma Latest Developments
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Information
11.10.2 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product Offered
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 BoomRay Pharmaceuticals Main Business Overview
11.10.5 BoomRay Pharmaceuticals Latest Developments
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Information
11.11.2 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 SmartNuclide Biopharma Main Business Overview
11.11.5 SmartNuclide Biopharma Latest Developments
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Information
11.12.2 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product Offered
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Hengrui Medicine Main Business Overview
11.12.5 Hengrui Medicine Latest Developments
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Information
11.13.2 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product Offered
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Yunnan Baiyao Group Main Business Overview
11.13.5 Yunnan Baiyao Group Latest Developments
11.14 Sinotau
11.14.1 Sinotau Company Information
11.14.2 Sinotau Radionuclide Drug Conjugates (RDC) Product Offered
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Sinotau Main Business Overview
11.14.5 Sinotau Latest Developments
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Information
11.15.2 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product Offered
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Hexin Pharmaceutical Main Business Overview
11.15.5 Hexin Pharmaceutical Latest Developments
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Information
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product Offered
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Main Business Overview
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Radionuclide Drug Conjugates (RDC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antibody Radionuclide Conjugates (ARC)
Table 4. Major Players of Peptide Radionuclide Conjugates (PRC)
Table 5. Major Players of Small Molecular Radionuclide Conjugates (SMRC)
Table 6. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Table 9. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Table 12. Global Radionuclide Drug Conjugates (RDC) Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player (2021-2026)
Table 14. Radionuclide Drug Conjugates (RDC) Key Players Head office and Products Offered
Table 15. Radionuclide Drug Conjugates (RDC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Table 20. Global Radionuclide Drug Conjugates (RDC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country (2021-2026)
Table 24. Americas Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Table 26. Americas Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Table 28. APAC Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Table 30. APAC Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country (2021-2026)
Table 34. Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Radionuclide Drug Conjugates (RDC)
Table 40. Key Market Challenges & Risks of Radionuclide Drug Conjugates (RDC)
Table 41. Key Industry Trends of Radionuclide Drug Conjugates (RDC)
Table 42. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. POINT Biopharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 47. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 48. POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. POINT Biopharma Main Business
Table 50. POINT Biopharma Latest Developments
Table 51. Telix Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 52. Telix Radionuclide Drug Conjugates (RDC) Product Offered
Table 53. Telix Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Telix Main Business
Table 55. Telix Latest Developments
Table 56. ITM AG Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 57. ITM AG Radionuclide Drug Conjugates (RDC) Product Offered
Table 58. ITM AG Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. ITM AG Main Business
Table 60. ITM AG Latest Developments
Table 61. Bayer AG Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 62. Bayer AG Radionuclide Drug Conjugates (RDC) Product Offered
Table 63. Bayer AG Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Bayer AG Main Business
Table 65. Bayer AG Latest Developments
Table 66. Novartis Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 67. Novartis Radionuclide Drug Conjugates (RDC) Product Offered
Table 68. Novartis Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Novartis Main Business
Table 70. Novartis Latest Developments
Table 71. Lantheus Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 72. Lantheus Radionuclide Drug Conjugates (RDC) Product Offered
Table 73. Lantheus Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Lantheus Main Business
Table 75. Lantheus Latest Developments
Table 76. Curium Pharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 77. Curium Pharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 78. Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Curium Pharma Main Business
Table 80. Curium Pharma Latest Developments
Table 81. Uihc Pet Imaging Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 82. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product Offered
Table 83. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Uihc Pet Imaging Main Business
Table 85. Uihc Pet Imaging Latest Developments
Table 86. Grand Pharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 87. Grand Pharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 88. Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Grand Pharma Main Business
Table 90. Grand Pharma Latest Developments
Table 91. BoomRay Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 92. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product Offered
Table 93. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. BoomRay Pharmaceuticals Main Business
Table 95. BoomRay Pharmaceuticals Latest Developments
Table 96. SmartNuclide Biopharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 97. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 98. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. SmartNuclide Biopharma Main Business
Table 100. SmartNuclide Biopharma Latest Developments
Table 101. Hengrui Medicine Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 102. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product Offered
Table 103. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Hengrui Medicine Main Business
Table 105. Hengrui Medicine Latest Developments
Table 106. Yunnan Baiyao Group Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 107. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product Offered
Table 108. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Yunnan Baiyao Group Main Business
Table 110. Yunnan Baiyao Group Latest Developments
Table 111. Sinotau Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 112. Sinotau Radionuclide Drug Conjugates (RDC) Product Offered
Table 113. Sinotau Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Sinotau Main Business
Table 115. Sinotau Latest Developments
Table 116. Hexin Pharmaceutical Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 117. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product Offered
Table 118. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Hexin Pharmaceutical Main Business
Table 120. Hexin Pharmaceutical Latest Developments
Table 121. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 122. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product Offered
Table 123. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Main Business
Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Latest Developments
Table 1. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Radionuclide Drug Conjugates (RDC) Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Antibody Radionuclide Conjugates (ARC)
Table 4. Major Players of Peptide Radionuclide Conjugates (PRC)
Table 5. Major Players of Small Molecular Radionuclide Conjugates (SMRC)
Table 6. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Table 9. Radionuclide Drug Conjugates (RDC) Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 11. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Table 12. Global Radionuclide Drug Conjugates (RDC) Revenue by Player (2021-2026) & ($ millions)
Table 13. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player (2021-2026)
Table 14. Radionuclide Drug Conjugates (RDC) Key Players Head office and Products Offered
Table 15. Radionuclide Drug Conjugates (RDC) Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 16. New Products and Potential Entrants
Table 17. Mergers & Acquisitions, Expansion
Table 18. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 19. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Table 20. Global Radionuclide Drug Conjugates (RDC) Revenue by Country/Region (2021-2026) & ($ millions)
Table 21. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Country/Region (2021-2026)
Table 22. Americas Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026) & ($ millions)
Table 23. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country (2021-2026)
Table 24. Americas Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 25. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Table 26. Americas Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 27. Americas Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Table 28. APAC Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 29. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Table 30. APAC Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 31. APAC Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 32. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2021-2026) & ($ millions)
Table 33. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country (2021-2026)
Table 34. Europe Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 35. Europe Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 36. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Region (2021-2026) & ($ millions)
Table 37. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Type (2021-2026) & ($ millions)
Table 38. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Application (2021-2026) & ($ millions)
Table 39. Key Market Drivers & Growth Opportunities of Radionuclide Drug Conjugates (RDC)
Table 40. Key Market Challenges & Risks of Radionuclide Drug Conjugates (RDC)
Table 41. Key Industry Trends of Radionuclide Drug Conjugates (RDC)
Table 42. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Region (2027-2032) & ($ millions)
Table 43. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Region (2027-2032)
Table 44. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Type (2027-2032) & ($ millions)
Table 45. Global Radionuclide Drug Conjugates (RDC) Market Size Forecast by Application (2027-2032) & ($ millions)
Table 46. POINT Biopharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 47. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 48. POINT Biopharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 49. POINT Biopharma Main Business
Table 50. POINT Biopharma Latest Developments
Table 51. Telix Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 52. Telix Radionuclide Drug Conjugates (RDC) Product Offered
Table 53. Telix Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 54. Telix Main Business
Table 55. Telix Latest Developments
Table 56. ITM AG Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 57. ITM AG Radionuclide Drug Conjugates (RDC) Product Offered
Table 58. ITM AG Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 59. ITM AG Main Business
Table 60. ITM AG Latest Developments
Table 61. Bayer AG Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 62. Bayer AG Radionuclide Drug Conjugates (RDC) Product Offered
Table 63. Bayer AG Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 64. Bayer AG Main Business
Table 65. Bayer AG Latest Developments
Table 66. Novartis Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 67. Novartis Radionuclide Drug Conjugates (RDC) Product Offered
Table 68. Novartis Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 69. Novartis Main Business
Table 70. Novartis Latest Developments
Table 71. Lantheus Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 72. Lantheus Radionuclide Drug Conjugates (RDC) Product Offered
Table 73. Lantheus Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 74. Lantheus Main Business
Table 75. Lantheus Latest Developments
Table 76. Curium Pharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 77. Curium Pharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 78. Curium Pharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 79. Curium Pharma Main Business
Table 80. Curium Pharma Latest Developments
Table 81. Uihc Pet Imaging Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 82. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product Offered
Table 83. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 84. Uihc Pet Imaging Main Business
Table 85. Uihc Pet Imaging Latest Developments
Table 86. Grand Pharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 87. Grand Pharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 88. Grand Pharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 89. Grand Pharma Main Business
Table 90. Grand Pharma Latest Developments
Table 91. BoomRay Pharmaceuticals Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 92. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product Offered
Table 93. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 94. BoomRay Pharmaceuticals Main Business
Table 95. BoomRay Pharmaceuticals Latest Developments
Table 96. SmartNuclide Biopharma Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 97. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product Offered
Table 98. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 99. SmartNuclide Biopharma Main Business
Table 100. SmartNuclide Biopharma Latest Developments
Table 101. Hengrui Medicine Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 102. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product Offered
Table 103. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 104. Hengrui Medicine Main Business
Table 105. Hengrui Medicine Latest Developments
Table 106. Yunnan Baiyao Group Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 107. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product Offered
Table 108. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 109. Yunnan Baiyao Group Main Business
Table 110. Yunnan Baiyao Group Latest Developments
Table 111. Sinotau Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 112. Sinotau Radionuclide Drug Conjugates (RDC) Product Offered
Table 113. Sinotau Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 114. Sinotau Main Business
Table 115. Sinotau Latest Developments
Table 116. Hexin Pharmaceutical Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 117. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product Offered
Table 118. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 119. Hexin Pharmaceutical Main Business
Table 120. Hexin Pharmaceutical Latest Developments
Table 121. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Details, Company Type, Radionuclide Drug Conjugates (RDC) Area Served and Its Competitors
Table 122. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product Offered
Table 123. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Main Business
Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Latest Developments
LIST OF FIGURES
Figure 1. Radionuclide Drug Conjugates (RDC) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Radionuclide Drug Conjugates (RDC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Radionuclide Drug Conjugates (RDC) Sales Market Share by Country/Region (2025)
Figure 8. Radionuclide Drug Conjugates (RDC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type in 2025
Figure 10. Radionuclide Drug Conjugates (RDC) in Neuroendocrine Tumors
Figure 11. Global Radionuclide Drug Conjugates (RDC) Market: Neuroendocrine Tumors (2021-2026) & ($ millions)
Figure 12. Radionuclide Drug Conjugates (RDC) in Prostate Cancer
Figure 13. Global Radionuclide Drug Conjugates (RDC) Market: Prostate Cancer (2021-2026) & ($ millions)
Figure 14. Radionuclide Drug Conjugates (RDC) in Renal Cell Carcinoma
Figure 15. Global Radionuclide Drug Conjugates (RDC) Market: Renal Cell Carcinoma (2021-2026) & ($ millions)
Figure 16. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application in 2025
Figure 17. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player in 2025
Figure 18. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 20. APAC Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 21. Europe Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 23. Americas Radionuclide Drug Conjugates (RDC) Value Market Share by Country in 2025
Figure 24. United States Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region in 2025
Figure 29. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 31. China Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country in 2025
Figure 38. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 54. APAC Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 55. Europe Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 57. United States Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 58. Canada Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 61. China Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 62. Japan Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 63. Korea Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 65. India Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 66. Australia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 67. Germany Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 68. France Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 69. UK Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 70. Italy Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 71. Russia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 74. Israel Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 76. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 1. Radionuclide Drug Conjugates (RDC) Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Radionuclide Drug Conjugates (RDC) Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Radionuclide Drug Conjugates (RDC) Sales Market Share by Country/Region (2025)
Figure 8. Radionuclide Drug Conjugates (RDC) Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type in 2025
Figure 10. Radionuclide Drug Conjugates (RDC) in Neuroendocrine Tumors
Figure 11. Global Radionuclide Drug Conjugates (RDC) Market: Neuroendocrine Tumors (2021-2026) & ($ millions)
Figure 12. Radionuclide Drug Conjugates (RDC) in Prostate Cancer
Figure 13. Global Radionuclide Drug Conjugates (RDC) Market: Prostate Cancer (2021-2026) & ($ millions)
Figure 14. Radionuclide Drug Conjugates (RDC) in Renal Cell Carcinoma
Figure 15. Global Radionuclide Drug Conjugates (RDC) Market: Renal Cell Carcinoma (2021-2026) & ($ millions)
Figure 16. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application in 2025
Figure 17. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Player in 2025
Figure 18. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Figure 19. Americas Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 20. APAC Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 21. Europe Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 22. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size 2021-2026 ($ millions)
Figure 23. Americas Radionuclide Drug Conjugates (RDC) Value Market Share by Country in 2025
Figure 24. United States Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 25. Canada Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 26. Mexico Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 27. Brazil Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 28. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region in 2025
Figure 29. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 30. APAC Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 31. China Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 32. Japan Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 33. South Korea Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 34. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 35. India Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 36. Australia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 37. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Country in 2025
Figure 38. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 39. Europe Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 40. Germany Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 41. France Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 42. UK Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 43. Italy Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 44. Russia Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 45. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Region (2021-2026)
Figure 46. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Type (2021-2026)
Figure 47. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Market Share by Application (2021-2026)
Figure 48. Egypt Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 49. South Africa Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 50. Israel Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 51. Turkey Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 52. GCC Countries Radionuclide Drug Conjugates (RDC) Market Size Growth 2021-2026 ($ millions)
Figure 53. Americas Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 54. APAC Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 55. Europe Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 56. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 57. United States Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 58. Canada Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 59. Mexico Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 60. Brazil Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 61. China Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 62. Japan Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 63. Korea Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 64. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 65. India Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 66. Australia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 67. Germany Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 68. France Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 69. UK Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 70. Italy Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 71. Russia Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 72. Egypt Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 73. South Africa Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 74. Israel Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 75. Turkey Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
Figure 76. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Type (2027-2032)
Figure 77. Global Radionuclide Drug Conjugates (RDC) Market Size Market Share Forecast by Application (2027-2032)
Figure 78. GCC Countries Radionuclide Drug Conjugates (RDC) Market Size 2027-2032 ($ millions)
